Kane Biotech
Kane Biotech is engaged in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. Our mission is to be a royalty based revenue company licensing our technologies to global industry players. Kane Biotech has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and commercialized products such as StrixNB™ and bluestem™, Kane's premium companion pet oral care products, and DispersinB® an antibiofilm enzyme for dermatology.
Kane Biotech has a number of DispersinB® formulations in development including formulations with antibiotics and other antibiofilm enzymes. Kane Biotech's other proprietary biofilm technologies have potential to treat human health conditions such as chronic inflammatory skin disorders, and can also be used in institutional, commercial, and industrial environments such as hospitals and food production.
Conference Objective
Kane’s primary objective is to discover and commercialize unique and compelling technologies that will prevent biofilm related infections in human and animal healthcare as well as biofilm related problems in institutional, commercial, and industrial applications. This includes our own patented and patent pending technologies as well as in-licensing opportunities
Partnering Objective
Kane’s commercial strategy is to create value for shareholders through the establishment of global partnerships and licensing agreements with leading companies to commercialize our innovations, backed by advanced clinical studies and regulatory and safety certifications. We are actively looking for out-licensing opportunities for:
Our pet specialty brand, bluestem™ for companion pet oral care;
Our veterinary brand, StrixNB™ for companion pet oral care (outside of North America);
Our companion pet dermatology technology, DispersinB® for otitis and skin infections;
Our catheter coating technology, Aledex®;
Our inflammatory skin disorder technology with applications in Athlete’s Foot, Atopic Dermatitis, and Seborrheic Dermatitis
Delegate Contacts
Mark Ahrens-Townsend joined Kane Biotech in May 2015 as President and CEO. Mr. Ahrens-Townsend brings extensive expertise in leadership, strategic planning, and business development. He has spent 30+ years in the Technology, Engineering and Venture Capital industries.
For the last 19 years Mr. Ahrens-Townsend has held senior executive roles, twice as President and CEO of two publicly traded technology companies, and has also served extensively on the boards and committees of several private and publicly held companies.
Mr. Ahrens-Townsend holds B.Sc. (Engineering) and MBA (Finance) degrees from the University of Manitoba
Grant Humphrey joined Kane Biotech as Vice President, Sales in July, 2016. Mr. Humphrey is an accomplished, award winning sales professional. An entrepreneur, he has invented, patented and developed a product from conception to market that is still being sold today. He possesses a hunter-like mentality that allows him to meet and exceed sales targets, and his ability to build relationships leads to successful partnerships across many industries both domestically and internationally.
He has experiences in veterinary and human healthcare, B2B and B2G marketing programs
Nanda Yakandawala joined Kane Biotech in 2003 and leads the Company’s research efforts.
Originally graduating with his B.Sc. from the University of Peradeniya in Sri Lanka, Dr. Yakandawala completed his M.Sc. in biotechnology at the University of Adelaide in Australia followed by his Ph.D. in molecular biology at the Swiss Federal Institute in Zurich. Dr. Yakandawala is a recognized expert in biofilms and is widely published in his field.